Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.34 |
| ▸ | BAZ2A | Q9UIF9 | 3/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950189 | 0.85 | ITGAV (0.40) | KMT2ABCAT2HSD11B1BMP1ITGAV | |
| SCHEMBL1949476 | 0.85 | HSD11B1 (0.38) | KMT2AMEN1BCAT2HSD11B1BMP1 | |
| SCHEMBL1927510 | 0.84 | BMP1 (0.37) | BCAT2HSD11B1BMP1ITGAVALDH1A1 | |
| SCHEMBL1926036 | 0.84 | HSD11B1 (0.40) | KMT2AMEN1BCAT2HSD11B1BMP1 | |
| SCHEMBL1925919 | 0.83 | L3MBTL1 (0.48) | KMT2AMEN1ALOX15HSD11B1TDP1 | |
| SCHEMBL1952111 | 0.82 | MEN1 (0.38) | KMT2AMEN1ALOX15BCAT2HSD11B1 | |
| SCHEMBL1948945 | 0.81 | CTDSP1 (0.37) | KMT2AMEN1ALOX15HSD11B1BMP1 | |
| SCHEMBL1952112 | 0.81 | BMP1 (0.38) | BCAT2HSD11B1BMP1ITGAVTDP1 | |
| SCHEMBL1948946 | 0.81 | BMP1 (0.38) | KMT2AMEN1BCAT2BMP1BAZ2B | |
| SCHEMBL1948801 | 0.81 | ALDH1A1 (0.48) | KMT2ABMP1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2509942-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | Johns Hopkins University (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071951-A2 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | KMT2A 1413/4885MEN1 3214/4885ALOX15 367/4885 |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | KMT2A 580/4885MEN1 3253/4885ALOX15 545/4885 |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, NOS2 | KMT2A 1464/4885MEN1 3326/4885ALOX15 351/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | KMT2A 1413/4885MEN1 3214/4885ALOX15 367/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | KMT2A 580/4885MEN1 3253/4885ALOX15 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.